You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems Inc            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Low Cost Laser Diagnostic for CD4+ T Cell Counting

    SBC: Mbio Diagnostics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop and commercialize a simple cell counter for routine enumeration of CD4 cells for management of HIV-infected individuals. HIV-1 mediated CD4 cell destruction is the centralimmunologic feature of HIV-1 infection. Thus, the CD4 count is a critical measurement in initial disease staging, in monitoring antiretroviral t ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. A new, rapidly dissolving and thermally stable dry powder Hepatitis-B vaccine

    SBC: AKTIV-DRY            Topic: NIAID

    DESCRIPTION (provided by applicant): The overarching goal of this project is to move a new, dry powder formulation of Hepatitis-B vaccine on its path to commercialization. In the Phase I SBIR we tested in vitro three Hep-B dry powder formulations of commercially available Shanvac-B and demonstrated powder stability and immunogenicity at temperatures ranging from -20 ?C through 65 oC. At these temp ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic

    SBC: CRESTONE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The alarming increase in incidence of infections caused by drug-resistant bacteria has created an urgent need for new antibacterial agents. We are developing a novel class of small molecule antibiotics ( TZUs ) targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. These agents exhibit broad-spectrum activity against Gram-positive bacteria, ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Robust, defined, animal-free cell culture medium for the production of vaccines

    SBC: VENTRIA BIOSCIENCE            Topic: NIAID

    DESCRIPTION (provided by applicant): The Vero cell line is used in the production of viral based vaccines. The use of cell based vaccines based on the Vero cell line is growing. The majority of the vaccines in use today are produced using cell culture medium supplemented with serum. The use of animal-derived products in vaccine culture media presents a risk for the transmission of infectious disea ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A Patient Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials

    SBC: PHARMATECH, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The American Cancer Society estimates that more than 1.5 million new cancer victims will be diagnosed this year in the U.S., and that ~572,000 Americans will die of cancer in 2011.1 More than 13 million Americans are living today with a history of cancer, and this number is heading toward 18 million by 2020.1 Beyond the human costs in lives, productivity, and q ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Computerized Stage-Matched Intervention for Juvenile Offenders

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Footwear-based physical activity biofeedback device for weight management

    SBC: PHYSICAL ACTIVITY INNOVATIONS. LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The number of adults and children who are overweight or obese continues to increase and has reached epidemic proportions. Obesity is due to a sustained positive energy balance (energy intake gt energy expenditure) and is typically coupled with low levels of physical activity (i.e. sedentary lifestyles). The combination of obesit and inactivity has resulted in i ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Beating-Heart Surgery for Heart Valve Replacement

    SBC: VALVEXCHANGE, INC.            Topic: NHLBI

    Each year, over 115,000 patients in the US need to have their diseased heart valves replaced with artificial devices. Although bioprosthetic valves are considered ideal, they wear out in about 15 years and are thus used primarily in the elderly who are notexpected to outlive the valve. Younger patients receive mechanical valves that are more durable, but require chronic anticoagulation. This makes ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government